Disease modification in OA — will we ever get there?

Research output: Contribution to journalDebate/Note/Editorial

Abstract

No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

Details

Authors
Organisations
External organisations
  • University of Southern Denmark
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Rheumatology and Autoimmunity
Original languageEnglish
JournalNature Reviews Rheumatology
Publication statusPublished - 2019 Feb 7
Publication categoryResearch
Peer-reviewedYes